Ramipril - synthetic anti-hypertensive drug.
Mode of action Ramipril
The active ingredient of the drug - ramipril, is a prodrug that is converted to ramiprilat in the body.
According to the instructions Ramipril significantly reduces the incidence of stroke, myocardial infarction and cardiovascular death with increased cardiovascular risk that arises as a result of cardiovascular diseases such as previous stroke, coronary heart disease or peripheral vascular disease.
The hypotensive effect of ramipril on reviews is a few hours after admission, which reaches a maximum for 3-6 hours. Typically, the hypotensive effect of the therapy continues at least a day.
Active ingredient ramipril exerts vasodilating effect and decreases total peripheral vascular resistance and increases stress tolerance.
Ramipril Review reduces the risk of sudden death in chronic heart failure after myocardial infarction, and also reduces the number of hospitalizations for heart failure.
Ramipril is released in the dosage form of tablets on 0, 0025 and 0 005 grams in blisters 28 pcs.
Analogues of ramipril active substance is drugs Ramazid H Hart, Dilaprel, Pyramus, Ramigamma, Tritatse, Amprilan, Triapin, Ramitren.
According to the instructions Ramipril is indicated for use in:
- Heart failure, developed in the first few days after an acute myocardial infarction;
- Chronic heart failure;
- Diabetic and non-diabetic nephropathy.
Also, the drug ramipril and analogues prescribed to reduce the risk of myocardial infarction, stroke and cardiovascular mortality, including:
- Confirmation of coronary artery disease with a history of heart attack or not;
- Transferred coronary artery bypass grafting or percutaneous transluminal coronary angioplasty;
- Peripheral arterial occlusive disease.
Ramipril and analogues are contraindicated in the following cases:
- Expressions of the kidneys and liver;
- Artery stenosis sole kidney;
- Bilateral renal artery stenosis;
- Age of 18 years;
- Condition after kidney transplantation;
- Aortic stenosis;
- Hypersensitivity to ramipril or auxiliary components of the drug, as well as other ACE inhibitors;
- Primary hyperaldosteronism;
According to the instructions Ramipril take no more than twice a day. Initial single dose usually is 1, 25-2, 5 mg, which, if necessary, can be gradually increased to be effective. The maintenance dose of ramipril is determined individually, depending on the indications for use of the drug and the effectiveness of the treatment.
If concomitant renal impairment dose of Ramipril is recommended for instruction be individualized, depending on the values of CC. At deficiency of fluid or sodium before use of the drug should carry out the correction of water and electrolyte imbalance.
Simultaneous administration of ramipril with insulin, metformin and hypoglycemic agents can cause hypoglycemia.
The development of hyperkalemia may or combined with potassium-sparing diuretics (including spironolactone, amiloride, triamterene), potassium supplements, salt substitutes.
Reduction of the antihypertensive effect may occur while ramipril with non-steroidal anti-inflammatory drugs, while the use of drugs, has a hypotensive effect, a therapeutic effect may increase.
The risk of leucopenia is increased while the use of cytostatics, allopurinol, procainamide and immunosuppressants.
Ramipril on responses often causes:
- Constipation or diarrhea, loss of appetite;
- Bronchitis, cough, sinusitis;
- Dizziness, weakness, and headache;
- Skin rash, angioedema and some other hypersensitivity reactions.
Violations of the urinary system developed primarily for existing renal impairment and are expressed as an increase in serum creatinine and blood urea and proteinuria. Violations of the hematopoietic system, such as neutropenia, thrombocytopenia, anemia and agranulocytosis when using the drug are less common.
Ramipril also on responses rarely causes:
- Stomach ache;
- Cholestatic jaundice;
- Sleep disorders and mood;
- Chest pain;
- Muscle cramps;
Ramipril belongs to the B list of antihypertensive drugs with a shelf life of no more than 36 months.